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Abstract
Myocardial infarction causes significant mortality and morbidity. Timely diagnosis allows clinicians to risk stratify their 
patients and select appropriate treatment. Biomarkers have been used to assist with timely diagnosis, while an 
increasing number of novel markers have been identified to predict outcome following an acute myocardial infarction 
or acute coronary syndrome. This may facilitate tailoring of appropriate therapy to high-risk patients. This review 
focuses on a variety of promising biomarkers which provide diagnostic and prognostic information.
Heart-type Fatty Acid Binding Protein and copeptin in combination with cardiac troponin help diagnose myocardial 
infarction or acute coronary syndrome in the early hours following symptoms. An elevated N-Terminal Pro-B-type 
Natriuretic Peptide has been well validated to predict death and heart failure following a myocardial infarction. 
Similarly other biomarkers such as Mid-regional pro-Atrial Natriuretic Peptide, ST2, C-Terminal pro-endothelin 1, Mid-
regional pro-Adrenomedullin and copeptin all provide incremental information in predicting death and heart failure. 
Growth differentiation factor-15 and high-sensitivity C-reactive protein predict death following an acute coronary 
syndrome. Pregnancy associated plasma protein A levels following chest pain predicts risk of myocardial infarction and 
revascularisation. Some biomarkers such as myeloperoxidase and high-sensitivity C-reactive protein in an apparently 
healthy population predicts risk of coronary disease and allows clinicians to initiate early preventative treatment. In 
addition to biomarkers, various well-validated scoring systems based on clinical characteristics are available to help 
clinicians predict mortality risk, such as the Thrombolysis In Myocardial Infarction score and Global Registry of Acute 
Coronary Events score. A multimarker approach incorporating biomarkers and clinical scores will increase the 
prognostic accuracy. However, it is important to note that only troponin has been used to direct therapeutic 
intervention and none of the new prognostic biomarkers have been tested and proven to alter outcome of therapeutic 
intervention.
Novel biomarkers have improved prediction of outcome in acute myocardial infarction, but none have been 
demonstrated to alter the outcome of a particular therapy or management strategy. Randomised trials are urgently 
needed to address this translational gap before the use of novel biomarkers becomes common practice to facilitate 
tailored treatment following an acute coronary event.
Introduction
Coronary artery disease (CAD) and its end result, myo-
cardial infarction (MI) continue to be a significant cause
of mortality and morbidity in the western world. Over the
past 50 years, it has become clear that the cascade of
thrombotic events following atherosclerotic plaque rup-
ture causes occlusion of the coronary artery, interrupting
blood supply and oxygen to myocardium thus resulting in
infarction. Myocardial necrosis following infarction is
followed by heart failure, myocardial rupture or arrhyth-
mias. Early treatment of myocardial ischaemia to prevent
necrosis with treatments such as fibrinolysis, coronary
artery bypass grafting and percutaneous coronary inter-
vention have improved outcome [1].
Over time it has become clear that in order for such
treatments to be of maximal benefit, timely diagnosis is
important. Here, biomarkers become important, to help
us improve our diagnostic accuracy of the disease, as
treatments are not without risk. Furthermore, biomarkers
also provide prognostic information about the disease,
which then aids clinicians in deciding how aggressively
they need to treat the disease. * Correspondence: lln1@le.ac.uk
2 Leicester National Institute for Health Research Cardiovascular Biomedical 
Research Unit, UK
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Definitions
Biomarkers are measurable and quantifiable biological
parameters which serve as indices for health and physiol-
ogy assessments [2]. This includes disease risk and diag-
nosis. The diagnosis of acute myocardial infarction
(AMI) [3] can be made with the detection of a rise/fall of
cardiac troponin (at least one value above the 99th percen-
tile of the upper reference limit) and one of 1) symptoms
of ischaemia, 2) electrocardiogram (ECG) changes of new
ischaemia, 3) new pathological Q waves or 4) imaging
evidence of new loss of viable myocardium.
Both the ECG and cardiac troponin are biomarkers, but
the focus of this review will be on serum proteins/mark-
ers which have become increasingly important to
improve our diagnosis of myocardial infarction, in some
cases identifying people at risk of having an infarct and in
others to predict long term prognosis following an actual
event.
What makes a good biomarker?
A good biomarker is something that is easily measured
and can be used as a surrogate marker for disease and its
severity [4]. For instance, blood sugar can be used to diag-
nose diabetes [5] whilst glycosylated haemoglobin
(HbA1c) monitors blood sugar control. Because cardio-
vascular disease continues to be a huge burden in most
countries, it is important to identify high risk patients in
order to prevent morbidity or mortality in later life. Med-
ications and treatments also come at a cost and therefore
simple and cheap tests have become increasingly neces-
sary to decide how to target treatment. A good biomarker
will diagnose or predict risk accurately (that is, high spec-
ificity and sensitivity), promptly provide affordable but
meaningful results, and should provide this incrementally
over existing markers or clinical characteristics.
Biomarkers in acute myocardial infarction
Some of these newer biomarkers and their relationship to
various pathophysiological processes are depicted in Fig-
ure 1.
Diagnostic biomarkers
Two well known biomarkers in use for diagnosis of acute
myocardial infarction are Creatine-Kinase-MB isoform
and Cardiac Troponin. In 2000, Cardiac Troponin
replaced CK-MB as the biomarker of choice for diagnos-
ing a myocardial infarction [6]. Troponin is a protein
released from myocytes when irreversible myocardial
damage occurs. It is highly specific to cardiac tissue and
accurately diagnoses myocardial infarction with a history
of ischaemic pain or ECG changes reflecting ischaemia.
Cardiac troponin level is dependent on infarct size [7],
thus giving clinicians an idea of the prognosis following
an infarct. However, following reperfusion therapy, the
actual troponin level can be misleading due to the wash-
out phenomenon. Troponin levels peak at 12 hours, and
stay elevated for 10 days or more. Whilst the use of Tro-
ponin for diagnosing AMI and risk stratification to aid
decision making has revolutionised the management of
patients presenting with chest pain, the 12-hour wait for
the levels to peak remains the Achilles heel of this bio-
marker. Newer, more sensitive troponin assays [8] have
been introduced to rectify this weakness. A positive Tro-
ponin is associated with increased risk of an adverse out-
come at 30 days (HR 1.96, P = 0.003). In addition, the
following two biomarkers may help facilitate early diag-
nosis of AMI, although neither has been compared with
the newer high sensitivity troponin assays.
C-terminal-provasopressin (Copeptin)
Copeptin is the more stable surrogate of arginine vaso-
pressin (AVP), with well-known effects on osmoregula-
tion and cardiovascular homeostasis [9]. Post AMI,
vasopressin is thought to (1) increase peripheral vasocon-
strictor activity thus increasing afterload and ventricular
stress [10]; (2) increase protein synthesis in myocytes
leading to hypertrophy [11] and (3) vasoconstriction of
coronary arteries. These effects are mediated via the V1
receptor, whilst effects on the V2 receptor mediate water
retention in the renal tubules. These receptors are now
targets for pharmacological therapy [12,13]. Copeptin is
Figure 1 Biomarkers associated with various pathophysiological processes associated with acute myocardial infarction.Chan and Ng BMC Medicine 2010, 8:34
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released in stoichiometric proportion to vasopressin and
is stable and easily assayed.
Copeptin can rule out MI earlier in addition to a nega-
tive Troponin T test [14]. At the time of presentation a
copeptin level of < 14 pg/ml and a Trop T level of < 0.01
could rule out a myocardial infarction with an area under
the curve (AUC) of receiver operating characteristic
curve (ROC) of 0.97 (negative predictive value of 99.7%),
thus obviating the need for monitoring and serial blood
tests in a majority of patients. Copeptin is a good marker
o f  n e u r o h o r m o n a l  s t r e s s ,  m a k i n g  i t  a l s o  u s e f u l  i n  r i s k
stratification in sepsis [15] and other diseases and hence
is not specific to the cardiovascular system.
Heart-Type Fatty Acid Binding Protein (H-FABP)
H-FABP is a low molecular weight protein involved in
myocardial fatty-acid metabolism [16]. It is also found in
small quantities in brain, kidney and skeletal tissue and
levels can go up in acute ischaemic strokes and intense
exercise. It is rapidly released early in myocardial infarc-
tion and necrosis into the cytosol. H-FABP has been
shown in mouse studies to be an early marker of ischae-
mia [17] (before morphological evidence of myocardial
necrosis) and can therefore help with diagnosis of MI ear-
lier [17-19]. However, studies attempting to use H-FABP
alone for early diagnosis of AMI have produced disap-
pointing results. One review of six studies found that the
pooled positive predictive value to be 65.8% and pooled
negative predictive value to be 82.0% [20]. Other more
recent studies demonstrated that H-FABP levels were
clearly associated with the composite end point of death,
myocardial infarction and heart failure at 10 months
[21,22]. When levels of H-FABP were measured post-
ACS and divided into quartiles, the top quartile was asso-
ciated with all-cause mortality 6.59 times higher than the
lowest quartile, after adjusting for hsCRP and Troponin.
In fact, when added to Troponin for risk stratification, a
negative troponin and H-FABP level < 5.8 mcg/L was
associated with zero mortality at six months; a negative
Troponin but H-FABP level > 5.8 mcg/L was associated
with a 4.93-fold increase in risk of death and 7.93-fold
increase in risk if Troponin was positive and H-FABP >
5.8 mcg/L.
Prognostic biomarkers
Before broaching the subject of biomarkers it is impor-
tant to note that as a result of various randomized control
trials and registry studies, various risk factors have been
identified and entered into scoring systems that allow a
clinician to risk stratify disease [23]. Popular tools include
the TIMI score [24], derived from the Thrombolysis in
Myocardial Infarction study, and the PURSUIT score [25]
(from Platelet glycoprotein IIb/IIIa in unstable angina:
Receptor sUppression using Integrillin Therapy). The
GRACE score is another particularly robust clinical tool
[26], which uses clinical indicators to calculate risk, (from
the Global Registry of Acute Coronary Events study), uti-
lizing weighted information about renal dysfunction, hae-
modynamic status, age, Killip Class, cardiovascular
history, and history of a cardiac arrest, as well as elevated
cardiac enzymes and type of ECG changes. On its own
this score has an excellent c-statistic of 0.84 for predicting
in-hospital death.
Newly introduced biomarkers should complement and
have incremental prognostic value over and above these
simple risk scores. It is therefore no surprise that bio-
markers providing prognostic information following an
acute coronary syndrome reflect the various physiologi-
cal pathways described in the GRACE score (for example,
haemodynamic status vs. biomechanical stress and neu-
rohumoral pathways). Currently, the only accepted bio-
marker affecting a change in management of a patient
with an acute coronary syndrome is the cardiac troponin.
1) Biomarkers of biomechanical stress
BNP/NTproBNP
One of the best known biomarkers of biomechanical
stress is the B-type Natriuretic Peptide (BNP). Secreted
b y  t h e  v e n t r i c l e s  i n  r e s po n s e  t o  ca r d i o m y ocyt e s  u n d e r
tension [27], BNP binds and activates receptors causing
reduction in systemic vascular resistance, central venous
pressure and natriuresis. BNP has been studied exten-
sively and provides prognostic information following an
MI [28-30]. This biomarker has a short half-life but is
released with the N-terminal portion of the pro-BNP
peptide (NTproBNP), a peptide much more stable in
serum and can be measured easily [31]. The understand-
ing of its biochemistry is far from complete, in particular
post-translational metabolism of the peptides, which may
affect accurate determination of the levels of active BNP
[32].
NTproBNP/BNP provides incremental information on
cardiovascular death at one year in the older population
above and beyond GRACE score [33]. On its own, it is at
least as good as the GRACE score when predicting in-
hospital mortality following AMI [34]; it also improves
the accuracy of the prognosis when added to the GRACE
score. In Non ST-elevation acute coronary syndromes
(NSTEACS), this biomarker predicts in-hospital and 180
day death or heart failure [35]. Studies are summarised in
Table 1[28-30,34-39].
The TACTICS-TIMI 18 study [35] randomized 1,676
patients to conservative vs. early invasive therapy.
Patients' BNP was measured within 24 hours and com-
pared. This study found that the six-month mortality if
BNP was below versus above cut-off of 80 pg/ml was 1.4%
versus 8.4%, and risk of mortality or congestive heart fail-
ure below versus above cut-off was 3.6% vs. 16.3%. How-Chan and Ng BMC Medicine 2010, 8:34
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ever, like another study [36], it did not identify patients
who would benefit from early invasive revascularisation.
Mid-Regional pro-Atrial Natriuretic Peptide (MRproANP)
Like BNP, ANP has similar neurohormonal effects and
has a similar secretory profile post AMI. Prior studies
have attempted to accurately measure levels of ANP and
N-ANP, with limited success [30,40]. N-ANP has been
demonstrated to be associated with late mortality follow-
ing AMI [41]. Such early N-ANP assays were often
affected by interferences and instability of analyte.
Because of disappointing results, ANP was thought to
provide limited prognostic information. However, the
discovery of the novel MRproANP fragment [42], a sub-
stantially more stable peptide compared to N-ANP and
ANP [43] due to the assay epitopes being located inter-
nally on the proANP molecule (and hence stability to
exoprotease activity), has led to the finding that
MRproANP is at least as good at predicting death and
heart failure as NTproBNP [44]. When MRproANP levels
were divided into quartiles, the top quartile was associ-
ated with a hazard ratio (HR) of 3.87 (vs. NTproBNP HR
3.25) predicting death at follow-up. Both biomarkers had
similar AUC of ROC (0.83). MRproANP is emerging
therefore to be an important predictor of adverse events
following an AMI.
Growth Differentiation Factor-15(GDF-15)
GDF-15 is a member of the Transforming Growth Factor
Beta cytokine superfamily. It is not normally expressed in
the heart, but under episodes of stress (for example,
ischaemia and reperfusion) its levels go up in a variety of
tissues, including cardiomyocytes. It has an antihypertro-
phic effect, demonstrated in knockout mice which
develop early cardiac hypertrophic growth following
pressure overload [45]. GDF-15 provides prognostic
information following an MI or ACS. One study found
that increasing tertiles of GDF-15 levels in patients pre-
senting with NSTEACS was associated with an increasing
risk (1.5%, 5% and 14.1% respectively) of death at one year
(AUC of ROC 0.757) [46]. Studies are summarised in
Table 2[46-49].
These findings were validated in ST-elevation MI
(STEMIs) [48] and prospectively validated in an unse-
lected group of patients with AMI, where GDF-15 was
found to be independently predictive of adverse events
(death and heart failure) [49]. One study (FRISC-II)
which randomized patients to conservative and early
invasive strategy in patients with NSTEMI found GDF-15
to predict death or recurrent MI in the conservative
group but not in the invasive group [47] suggesting that
GDF-15 improves patients selection for early invasive
strategy. It also directly compared the use of Troponin T
vs the use of GDF-15 to select patients for early invasive
therapy. Troponin-positive patients but with a GDF-15
level < 1,200 ng/L had no mortality benefit from early
invasive therapy.
Table 1: Summary of studies using BNP or NTproBNP for ris stratification of AMI
Study Pop N Endpoints Thresholds Odds ratio or Hazard Ratio Ref
ACS-TIMI16 2,525 Death (30 day, 10 months) HF(10 months) 
MI (10 months)
Quartiles BNP > 80 pg/ml 1, 3.8, 4.0, 5.8 Approximately 
2.7 Approximately 2
[28]
AMI 70 Death (18 months) Median (>59 pg/ml) Approximately 2.5 [29]
AMI-CONSENSUS 131 Death (one year) 75th centile BNP 33.3 pmol/L Approximately 1.36 [30]
ACS 609 Death Median 2.4 [37]
NSTEACS 1,483 Death (in hosp) (180 days) BNP > 586 pg/ml (1.7) (1.67) [38]
FRISC-II 2,019 Death Top Tertile 4.1(invasive) vs 3.5(non-
invasive)
[36]
TACTICS-TIMI18 1,676 Death (six months) HF (30 days) BNP > 80 pg/ml OR 3.3 OR 3.9 [35]
ACS 1,033 Death (30 day) (six months) Quartiles (2.24) (1.84) [34]
AMI 473 Death Median OR 3.82 [39]Chan and Ng BMC Medicine 2010, 8:34
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However, GDF-15 is not specific for cardiovascular dis-
orders and has been found to be elevated in a variety of
malignancies (prostate, colon, glial).
ST2
ST2 is an IL1-receptor-like protein which was found to be
elevated in serum of hearts under mechanical stress [50].
ST2 predicts cardiovascular death following ACS [51].
ST2 turned out to be the target for an Interleukin called
IL-33 which seems to have a cardioprotective role, and
only appears when myocytes are under biomechanical
stress [52]. In mouse studies, IL-33 was found to mark-
edly antagonize angiotensin-II and phenylephrine-
induced cardiomyocyte hypertrophy. It is thought that
ST2/IL33 interaction also reduces atheroma burden [53].
P o s t  A M I  t h o u g h ,  i t  c o r r e l a t e s  s o m e w h a t  w i t h
NTproBNP [54], and both these biomarkers predict death
after MI (at six months) or heart failure. Investigations
into the use of IL33/ST2 pathway activation as a thera-
peutic target are still ongoing [55]. ST2 is also elevated in
acute asthma [56] and autoimmune disease [57]. The
specificity of ST2 to myocardial tissue stretch will need to
be determined before it can be used at the bedside [58].
ET1/CTproET1
Endothelin-1 or the more stable C- T erminal portion of
pro-Endothelin-1(CTproET1) has also been found to be
predictive of death or heart failure following an AMI [59].
ET1 is a potent vasoconstrictor peptide found originally
in vascular endothelial cells but has subsequently been
isolated in pulmonary, renal and smooth muscle cells
[60]. It activates ETA and ETB receptors; ETA receptors
are located predominantly on smooth muscle tissue of
blood vessels, mediating vasoconstriction and sodium
retention, whereas ETB receptors are located predomi-
nantly on endothelial cells mediating nitric oxide release,
natriuresis and diuresis [61]. Endothelin appears to be
detrimental post-MI, extending the infarct [62] and
reducing coronary blood flow [63]. It is also grossly ele-
vated following cardiogenic shock [64]. ET-1 is very
unstable and measuring its levels can be problematic due
to binding with receptors and other proteins. However
CTproET1 is a stable by-product of the release of the pre-
cursor which indirectly measures activity of the endothe-
lial system. ET1 is increased in proportion to the severity
of the disease post AMI [65,66]. Likewise CTproET1 is
also elevated post-MI, and levels above the median pre-
dict death or heart failure (HR 5.71, P= 0.002). This vari-
able is independent of age, Killip class and past medical
history. Plasma concentration of CTproET-1 peaks at Day
2 [59].
2) Biomarkers of neurohormonal pathway activation
Mid-Regional-pro-Adrenomedullin (MRproADM)
Adrenomedullin was first identified in human phaeo-
chromocytoma cells [67]. It is highly expressed in
endothelial cells [68]. Adrenomedullin mediates an
increase in cAMP with resultant vasodilatation and
hypotension [69]. Its other roles have not been well
defined, but some have suggested a cardioprotective role
at the time of the insult. The activity of adrenomedullin in
the cardiovascular system is similar to that of BNP; that
is, increase of nitric oxide production causing vasodilata-
tion, natriuresis and diuresis [70-72]. Like BNP it is
released in proportion to the severity of heart failure
[73,74], and is inversely related to the left ventricular
ejection fraction (LVEF)[75,76]. Adrenomedullin (ADM)
is difficult to measure in plasma as it is partially com-
plexed with complement [77]; in addition it is also rapidly
cleared from the circulation. Indirect quantification of
this peptide can be made by measuring the mid-regional
fragment of the proAdrenomedullin peptide, which is
more stable and secreted in equimolar concentrations as
ADM. Initial studies with ADM have produced conflict-
ing results as to the prognostic value of the peptide [40].
However, a recent study using the more stable
MRproADM has shown that post AMI, increased
MRproADM was associated with death, heart failure or
both at one year, over and above information gained from
NTproBNP alone [78]. Combining the two markers
Table 2: Summary of studies using GDF-15 for risk stratification of AMI
Study Pop N Endpoints Thresholds Odds ratio or Hazard Ratio Ref
GUSTOIV (NSTEACS) 2,081 + 429 Death (one year) Tertiles < 1,200 ng/L, 1,200 to 1,800 ng/L > 
1,800 ng/L
1.5%, 5%, 14.1% [46]
FRISC-II (invasive vs 
conservative)
2,079 Death or MI (2 yrs) Invasive at > 1,800 ng/L Invasive 1,200 to 
1,800 ng/L Invasive < 1,200 or Trop -ve





741 Death (1 yr) Tertiles < 1,200, 1,200 to 1,800, > 1,800 2.1%, 5.0%, 14% [48]
AMI 1,142 Death or HF (1.5 yr) <1,470 ng/L, >1,470 ng/L HR 1.77 [49]Chan and Ng BMC Medicine 2010, 8:34
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increased the AUC of the ROC from 0.77 and 0.79 to
0.84. MRproADM is very similar to NTproBNP, it is
higher in females than males, and is increased with age.
Copeptin
The same study group also investigated Copeptin as a
prognostic biomarker. They found that Copeptin pre-
dicted mortality or heart failure at 60 days post AMI [79].
In addition, the relationship of copeptin to LV dysfunc-
tion persisted for a prolonged period after the acute event
[80]. Copeptin provided complementary prognostic
information to NTproBNP, increasing the AUC of the
ROC from 0.76 and 0.79 to 0.84.
Figure 1 is a summary of the Kaplan-Meier event free
survival curves for some of the above mentioned bio-
markers (namely NTproBNP, MRproANP, MRproADM,
CTproET, copeptin, GDF-15 and ST2) in a prospectively
collected cohort of AMI patients (derived from the Leic-
ester Acute Myocardial Infarction Peptide (LAMP) study,
illustrating the events associated with biomarker
quartiles over about seven years. All of these biomarkers
significantly predict major adverse events following AMI
(Figure 2).
3) Biomarkers of plaque instability and inflammation
HsCRP (High-sensitivity C-reactive Protein)
Acute coronary syndromes are caused by vulnerable
plaques. It is thought that one of the driving forces caus-
ing atheromatous plaques to rupture or erode, causing a
cascade of events leading to coronary artery occlusion, is
inflammation in the plaques. An elevated C-reactive pro-
tein measured in seemingly healthy adults was associated
with increased cardiovascular risk [81,82]. CRP itself
mediates atherothrombosis [83-87]. This is supported by
a fairly large body of evidence. Newer, higher sensitivity
assays of CRP that detect lower levels of CRP (<5 mg/L)
risk stratify patients into low, intermediate and high risk,
with intermediate and high risk individuals benefiting
from aggressive therapy [88]. While the benefits of
HsCRP testing in a primary setting to screen for ischae-
mic heart disease is very clear, its use post-ACS or -MI is
less clear. CRP is elevated post-acute coronary syndrome
almost exclusively in the setting of myocardial necrosis
indicating the level of myocardial inflammation.
One study found that CRP measurements (taken
between 12 and 24 hours post event) predicted occur-
rence of heart failure (HR = 2.6, P = 0.04) and death (HR
= 2.7, P = 0.02) post-MI [89]. Elevated peak CRP in the
early phase of MI was related to early mechanical compli-
cations, including cardiac rupture [90], ventricular aneu-
rysm and thrombus formation. CRP levels post-MI peak
at two to four days, then take 8 to 12 weeks to subside to
baseline levels. Interestingly, CRP levels post acute MI do
not predict re-infarction. Additional acute coronary
events can only be predicted after CRP levels have
receded to baseline levels (after about 12 weeks).
One of the difficulties with CRP is that it is non-specific
in the presence of other inflammatory conditions (rheu-
matoid arthritis, malignancy, vasculitis). A new assay for
Human Pentraxin 3 is now available. Human Pentraxin 3
is an isoform which is secreted exclusively in vascular
endothelium and therefore may be more specific to the
vascular plaque inflammatory activity [91]. It remains to
Figure 2 Kaplan-Meier survival curves for quartiles of various biomarkers in 1,455 unselected AMI patients.
Chan and Ng BMC Medicine 2010, 8:34
http://www.biomedcentral.com/1741-7015/8/34
Page 7 of 11
be seen if this biomarker can provide incremental infor-
mation.
Myeloperoxidase (MPO)
Leucocytes play a central role in atherosclerotic plaque
rupture [92-96]. Myeloperoxidase in leucocytes may acti-
vate metalloproteinases and inactivate plasminogen acti-
vator inhibitor. Leucocytes also consume nitric oxide
catalytically, causing vasoconstriction and endothelial
dysfunction. Myeloperoxidase has been found in ather-
omatous plaques [96]. Patients with chronic angina have
circulating neutrophils with large quantities of MPO,
which decrease substantially post-ACS [97].
One trial showed that post-acute coronary syndrome
MPO levels higher than median predicted future death
and MI at one year [98]. It also found that after an AMI,
MPO levels peak early, then decrease over time and do
not correlate with Troponin or the neutrophil count. It is
not affected by fibrinolytic therapy but it is unclear if it is
affected by Primary Intervention. MPO levels do not pre-
dict heart failure. MPO levels higher than the median,
though, predict death or MI after one year [99,100],
whether or not NTproBNP level is below or above
m e d i a n .  T h e  r i s k  i s  m u c h  h i g h e r  i f  b o t h  M P O  a n d
NTproBNP levels are above the median.
Two population studies show that MPO (and CRP) in
healthy individuals are both associated with future devel-
opment of CAD [101,102].
Collectively the current evidence supports the need for
further studies into the actual role of MPO, and whether
elevated MPO levels in the serum directly correlates with
MPO released from circulating neutrophils.
Pregnancy associated Plasma Protein A (PaPPA)
PaPPA is a proatherosclerotic metalloproteinase [103]
which is highly expressed in unstable plaques and their
extracellular matrices [104]. It is not expressed in stable
plaques. Circulating PaPPA has been found to be much
higher in unstable angina and AMI, correlating also with
insulin-like growth factor and CRP, but not with Tro-
ponin. Interestingly, PaPPA > 2.9 mIU/L predicts a 4.6-
fold increase in risk of cardiovascular death, MI or revas-
cularisation even without a raised Troponin [105]. Its
mode of action of cleaving insulin-like growth factor 1
(IGF-1) was found to counteract endothelial dysfunction
by binding to high affinity binding sites in the endothe-
lium which then triggers nitric oxide release. PaPPA has
been isolated in other damaged tissue promoting repair,
giving it an inflammation repressor role [106].
Like CRP , PaPP A is expressed when there is a heavy
burden of unstable atheromatous plaque, including in
carotid arteries [107]. It also predicts risk of cardiovascu-
lar death [105]. Unlike CRP, it does not predict heart fail-
ure. Instead, it predicts future MI and revascularisation.
Evidence for the use of this biomarker clinically remains
scarce and whilst promising, more studies and standard-
ized assays will be needed to improve its clinical utility.
4) Other Novel biomarkers
MMP9, MMP2, TIMP1
The structural integrity of myocardial Extracellular
Matrix (ECM) is dependent on endogenous zinc-depen-
dent endopeptidases known as matrix metalloproteinases
(MMP). These enzymes are regulated by tissue inhibitors
of metalloproteinases (TIMPs). MMPs may degrade myo-
cardial ECM leading to the development of LV dilatation
and heart failure and their inhibition in experimental
models of AMI has been associated with reduced LV dila-
tation and wall stress. Although NTproBNP, TIMP1 and
MMP 9 were associated with cardiovascular death, heart
failure or both, they were not associated with re-infarc-
tion [108]. MMP2 is also elevated post MI [109] and is
associated with poor prognosis [110]. MMP3 peaks at 72
hours and plateau levels are associated with increase in
LV volume and a lower ejection fraction at follow up
[111].
Stability of biomarkers
Many of the new biomarkers introduced have enhanced
stability  in vitro, so that preanalytical contributions to
variation are minimised to some extent. For example, the
midregional epitopes assayed in MRproANP and
MRproADM are less susceptible to exoprotease action,
and prohormone fragment assays tend to be more stable
than assays for the actual hormone (for example,
NTproBNP, CTproET1, copeptin).
Future directions
Although there are large numbers of emerging novel bio-
markers, our understanding of the roles and biochemistry
of these various peptides in the disease process is still
fairly limited. It is difficult to draw specific conclusions
from the current body of evidence regarding the mecha-
nisms through which a biomarker could affect the prog-
nosis. Many of the studies use death or major adverse
cardiovascular events as endpoints because they are easy
to measure, but either of these endpoints could be a cul-
mination of a variety of pathophysiological processes. As
such, currently available biomarkers have not been able to
add much to helping us tailor our treatment (over and
above Troponin). Randomised trials based on the use of
biomarkers to alter therapy would be very informative.
Although there is evidence that combining biomarkers
may increase the accuracy of the tests, the best combina-
tions for diagnosis or prognosis need to be defined. Some
analogies can be drawn from heart failure studies;
NTproBNP has been used as a biomarker for diagnosis of
heart failure [112]. It does not provide clinicians with
information about the aetiology nor which specific treat-Chan and Ng BMC Medicine 2010, 8:34
http://www.biomedcentral.com/1741-7015/8/34
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ments to initiate. It does however guide therapy [113], as
a surrogate marker of disease severity.
There is some evidence that a multi-marker strategy
can improve diagnosis, risk stratification and prognosti-
cation of patients [114]. Of the above biomarkers, the
ones most likely to be adopted into bedside practice in
the near future are NTproBNP, MRproANP,MRproADM,
copeptin and GDF-15. The theoretical benefit of a multi-
marker approach would be tailored therapy as each bio-
marker would measure a separate disease sub-process. A
multi-marker panel of tests could then be used to create
an algorithm to aid clinical-decision making. We are,
however, a long way from this eventual goal.
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